Massimiliano Mistrangelo

Dr. Massimiliano Mistrangelo

orcid
M.D, PhD

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2020 in Techniques in Coloproctology
Verified
Journal Article
Open access
PDF file
GGG. Gallo
G. Gallo
JMJ. Martellucci
J. Martellucci
ASA. Sturiale
A. Sturiale
GCG. Clerico
G. Clerico
GMG. Milito
G. Milito
MTM. Trompetto
M. Trompetto
Hemorrhoidal disease (HD) is the most common proctological disease in the Western countries. However, its real prevalence is underestimated due to the frequent self-medication.The aim of this consensus statement is to provide evidence-based data to allow an individualized and appropriate management and treatment of HD. The strategy used to search for evidence was based on application of electronic sources such as MEDLINE, PubMed, Cochrane Review Library, CINAHL, and EMBASE.These guidelines are inclusive and not prescriptive.The recommendations were defined and graded based on the current levels of evidence and in accordance with the criteria adopted by American College of Chest Physicians. The recommendations were graded A, B, and C.

1 November 2019 in Annals of Surgery
Verified
Journal Article
Closed access
MAMarco E. Allaix
Marco E. Allaix
MDMaurizio Degiuli
Maurizio Degiuli
MBMarco A. Bonino
Marco A. Bonino
AAAlberto Arezzo
Alberto Arezzo
Massimiliano MistrangeloMassimiliano Mistrangelo
Massimiliano Mistrangelo
MMMario Morino
Mario Morino
Objectives: The aim of the study was to determine whether there are clinically relevant differences in outcomes between laparoscopic right colectomy (LRC) with intracorporeal ileocolic anastomosis (IIA) and LRC with extracorporeal IA (EIA). Background: IIA and EIA are 2 well-established techniques for restoration of bowel continuity after LRC. There are no high-quality studies demonstrating the superiority of one anastomotic technique over the other. Methods: This is a double-blinded randomized controlled trial comparing the outcomes of LRC with IIA and LRC with EIA in patients with a benign or malignant right-sided colon neoplasm. Primary endpoint was length of hospital stay (LOS). This trial was registered with ClinicalTrials.gov, number NCT03045107. Results: A total of 140 patients were randomized and analyzed. Median operative time was comparable in IIA versus EIA group {130 [interquartile range (IQR) 105–195] vs 130 (IQR 110–180) min; P = 0.770} and no intraoperative complications occurred. The quicker recovery of bowel function after IIA than EIA [gas: 2 (IQR 2–3) vs 3 (IQR 2–3) days, P = 0.003; stool: 4 (IQR 3–5) vs 4.5 (IQR 3–5) days, P = 0.032] was not reflected in any advantage in the primary endpoint: median LOS was similar in the 2 groups [6 (IQR 5–7) vs 6 (IQR 5–8) days; P = 0.839]. No significant differences were observed in the number of lymph nodes harvested, length of skin incision, 30-day morbidity (17.1% vs 15.7%, P = 0.823), reoperation rate, and readmission rate between the 2 groups. Conclusions: LRC with IIA is associated with earlier recovery of postoperative bowel function than LRC with EIA; however, it does not reflect into a shorter LOS.

28 June 2011 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MAM E Allaix
M E Allaix
FRF. Rebecchi
F. Rebecchi
CGC. Giaccone
C. Giaccone
Massimiliano MistrangeloMassimiliano Mistrangelo
Massimiliano Mistrangelo
MMMario Morino
Mario Morino

16 May 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAlessandra Beano
Alessandra Beano
ESElena Signorino
Elena Signorino
AEAndrea Evangelista
Andrea Evangelista
DBDavide Brusa
Davide Brusa
Massimiliano MistrangeloMassimiliano Mistrangelo
Massimiliano Mistrangelo
LMLina Matera
Lina Matera
Background: Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by triggering FcγRIII on natural killer (NK) cells. This study addresses the correlation between overall NK function and trastuzumab's clinical activity. Subjects and methods: Clinical and immunological responses were assessed in 26 patients receiving trastuzumab monotherapy as maintenance management after chemotherapy (8 mg/kg load and then standard doses of 6 mg/kg every 3 weeks). Cytotoxic activity against the MHC class I-negative standard NK target K562 cell line and HER2-specific ADCC against a trastuzumab-coated Her2-positive SKBR3 cell line were assessed in peripheral blood mononuclear cells (PBMC) harvested after the first standard dose. After six months, seventeen patients were scored as responders and nine as non-responders according to the RECIST criteria, while Progression-Free Survival (PFS) was calculated during a 12 months follow-up. Results: The responders had significantly higher levels of both NK and ADCC activities (p < 0.05) that were not different from those of eleven normal controls. The NK activity of the non-responders was significantly (p < 0.05) lower than that of the normal controls. At twelve months, there was a marked correlation between PFS and NK activity only. PFS was significantly longer in patients with high levels of NK activity, whereas its pattern was unrelated to high or low ADCC activity. Conclusion: One of the mechanisms of action of trastuzumab is NK cell-mediated ADCC lysis of the Her2-positve target cell. We show here that its potency is correlated with the short-term response to treatment, whereas longer protection against tumor expansion seems to be mediated by pure NK activity.

1 September 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
Massimiliano MistrangeloMassimiliano Mistrangelo
Massimiliano Mistrangelo
EPEttore Pelosi
Ettore Pelosi
MBMarilena Bellò
Marilena Bellò
URUmberto Ricardi
Umberto Ricardi
EMEnrica Milanesi
Enrica Milanesi
MMMario Morino
Mario Morino

24 September 2015 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
MTM. Trompetto
M. Trompetto
GCG. Clerico
G. Clerico
GCG. F. Cocorullo
G. F. Cocorullo
PGP. Giordano
P. Giordano
FMF. Marino
F. Marino
CRCarlo Ratto
Carlo Ratto